ES2659577T3 - Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina - Google Patents

Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina Download PDF

Info

Publication number
ES2659577T3
ES2659577T3 ES05793645.2T ES05793645T ES2659577T3 ES 2659577 T3 ES2659577 T3 ES 2659577T3 ES 05793645 T ES05793645 T ES 05793645T ES 2659577 T3 ES2659577 T3 ES 2659577T3
Authority
ES
Spain
Prior art keywords
formula
added
compound
ipa
naoh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05793645.2T
Other languages
English (en)
Inventor
Donald R. Gauthier
Richard Desmond
Paul N. Devine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals International GmbH
Original Assignee
Teva Pharmaceuticals International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceuticals International GmbH filed Critical Teva Pharmaceuticals International GmbH
Application granted granted Critical
Publication of ES2659577T3 publication Critical patent/ES2659577T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un proceso para preparar un compuesto de fórmula I: **(Ver fórmula)** o una sal farmacéuticamente aceptable del mismo, que comprende: oxidar un sulfuro de fórmula II: **(Ver fórmula)** con un agente catalizador de la oxidación y un oxidante; para dar un compuesto de fórmula III: **(Ver fórmula)** seguido por la reducción catalítica del compuesto de fórmula III; para dar el compuesto de fórmula I:: **(Ver fórmula)** o una sal farmacéuticamente aceptable del mismo.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
Sulfona-alqueno
247,41 (teórico= 3,17 kg)
Se hizo una lechada del alcohol en tolueno y se agregó ácido sulfúrico. Se calentó la reacción a reflujo entre 1 y 2 horas con separación azeotrópica de agua. Al finalizar, la reacción se enfrió a 70 °C y se agregó agua. La reacción se enfrió a RT y se separaron las fases. Se agregó tolueno (6 L/kg) y NaOH 5 N (2 eq., 1,6 L/kg,
5 pH>9) a la fase acuosa manteniendo la temperatura a < 30 °C. Se separaron las fases y se trató la fase orgánica con ácido sulfúrico 1 N (1 eq. de H2SO4, ~8 L/kg, pH~1). Se separaron las fases y se transfirió la fase acuosa directamente a la reacción de oxidación.
EJEMPLO 3
imagen7
Materiales
PM Cantidad Moles Densidad
Sulfuro-alqueno
247,41 3,30 kg 13,34
Na2WO4 x H2O
329,85 43,9 g 0,133
H2O2 al 30%
34,01 3,78 kg (3,41 L) 33,35 1,110
NaOH 5 N (1,5 ml/g Teórico)
5,6 L 12,0
NaOH 1 N
5,6 L
Solución salina al 20%
5,6 L
Tolueno (5 ml/g Teórico)
19 L
n-hetano
22,4 L
Sulfona-alqueno
279,41 (Teórico: 3,73 kg) 13,34
Na2SO3
126,04 0,84 kg 6,67
10
A una solución de sulfuro-alqueno en H2SO4 acuoso se agregó Na2WO4 x 2H2O. H2O2 (30%) se agregó en un periodo entre de 0,5 y 1 h manteniendo la temperatura por debajo de 55 °C. La mezcla resultante se dej ó asentar entre 50 y 55 °C hasta que el intermediario de sulfóxido alcance una cantidad de <0,5 A% (entre 1 y 2 h). La mezcla resultante se enfrió a 10 °C y se agr egó tolueno (5 L/kg) seguido por NaOH 5 N manteniendo la 15 temperatura interna <30 °C. Se separó la fase acuos a y se lavó la capa de tolueno con NaOH 1 N, seguido por un lavado con solución salina al 20%. La capa de tolueno típicamente da entre 85 y 90% de rendimiento. La reacción se concentró a 3 ml/g de volumen total (10 L) tiempo durante el cual cristalizó la sulfona-alqueno a partir de la solución. Se entibió la solución a entre 50 y 55 °C y se agregó heptano (3 mL/g) mantenie ndo la temperatura interna entre 50 y 55 °C. A la solución resultante se agregó más heptano (3 ml/g) a una
8
temperatura entre 50 y 55 °C en 1 hora. La lechada resultante se enfrió a 23 °C en un periodo de entre 0,5 y 1h, se dejó asentar durante 0,5 h y se filtró a temperatura ambiente. La torta del filtro se lavó con 1:3 tolueno/heptano (4 mL/g, 12 L) y luego se secó a 50 °C al vacío con una purga d e N2. El rendimiento típico fue entre 75 y 80 %, con >99 % en peso y 99 A% de pureza. Sobre las fases acuosas combinadas (capa acuosa después de NaOH 5 N, después de lavar con NaOH 1 N, después de lavar con solución salina al 20%) a 23 °C se agregó Na2SO3 sólido hasta que la prueba de peróxidos dio negativa mediante tiras reactivas Quantofix. Se registra una exoterma de ~3 °C.
EJEMPLO 4
en
Materiales
PM Cantidad Moles Densidad
Sulfona-alqueno
279,41 3,00 kg 10,74
Pd/C al 10%
600 g
HCO2H
46,02 2,47 kg (2,03 L) 53,68 (5 eq.) 1,22
IPA
15 L
H2O
6 L
Base libre
281,41 (Teórico = 3,02 kg) 10,74
NaOH 5 N
7,5 L 37,58 (3,5 eq.)
MTBE (10 ml/g)
30 L
H2O (3 ml/g)
9,0 L
HCl 5N en IPA
2,58 L 12,88 (1,2 eq.)
IPA (9,2 mL/g)
27,6 L
sal de HCl
317,88 (Teórico = 3,41 kg) 10,74
10
Se agregó HCO2H (5 eq.) a una lechada de sulfona-alqueno en IPA. A la solución resultante se agregó una suspensión de Pd/C al 10% en agua (5 ml/g). Se dejó asentar la suspensión a RT entre 16 y 24 h hasta que la sulfona-alqueno fue <0,10 A%. Se filtró el lote a través de una almohadilla de solka floc y se lavó la torta del filtro con 1:1 IPA/agua (2 mL/g). El ensayo típico de la combinación de filtrado y lavado tuvo entre 95 y 98 % de 15 rendimiento. Se transfirió el filtrado a un recipiente de extracción de 100 L conteniendo NaOH 5 N y MTBE preenfriado a 15 °C. Se separó la fase acuosa y se lavó la fase de MTBE con H2O (3 mL/g). La capa de MTBE se concentró a 4 ml/g de volumen total (12 L), se lavó rápidamente con IPA (2 x 5 ml/g) para eliminar el MTBE y el agua, luego se diluyó a 9 ml/g en IPA (contenido de H2O típico de entre 0,5 y 1%). Se entibió el filtrado a 65 °C y se agregó HCl 5 N en IPA. La lechada result ante se calentó a entre 75 y 80 °C hasta que todos los 20 sólidos estén disueltos. Se enfrió lentamente la solución se le agregó sal de HCl pura a entre 65 y 70 °C. Se
9
dejó asentar la lechada a entre 65 y 70 °C durante 1 hora y luego se enfrió lentamente a 23 °C en 1 h. Se filtró la lechada, se lavó con IPA (3 ml/g), y se secó sobre N2.
10

Claims (1)

  1. imagen1
    imagen2
    imagen3
ES05793645.2T 2004-10-13 2005-10-13 Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina Expired - Lifetime ES2659577T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61819604P 2004-10-13 2004-10-13
US618196P 2004-10-13
PCT/EP2005/011020 WO2006040155A1 (en) 2004-10-13 2005-10-13 Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine

Publications (1)

Publication Number Publication Date
ES2659577T3 true ES2659577T3 (es) 2018-03-16

Family

ID=35478927

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05793645.2T Expired - Lifetime ES2659577T3 (es) 2004-10-13 2005-10-13 Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina

Country Status (14)

Country Link
US (1) US7923459B2 (es)
EP (1) EP1802573B1 (es)
JP (1) JP4891908B2 (es)
KR (1) KR101319235B1 (es)
CN (1) CN101056854B (es)
AU (1) AU2005293754B2 (es)
CA (1) CA2584831C (es)
DK (1) DK1802573T3 (es)
ES (1) ES2659577T3 (es)
HU (1) HUE029790T2 (es)
MX (1) MX2007004215A (es)
NZ (1) NZ555094A (es)
PL (1) PL1802573T3 (es)
WO (1) WO2006040155A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE0401465D0 (sv) 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
KR101245075B1 (ko) 2004-06-08 2013-03-18 엔에스아베 필리알 아프 뉴로서치 스웨덴 아베 스베리게 도파민 신경전달의 모듈레이터로서 신 2기치환된페닐피페리딘/피페라진
WO2006040155A1 (en) 2004-10-13 2006-04-20 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
CA2584833A1 (en) * 2004-10-13 2006-04-20 Neurosearch Sweden Ab Process for the synthesis of 4-(3-sulfonylphenyl)-piperidines
WO2008127188A1 (en) * 2007-04-12 2008-10-23 Allbay Ab N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
WO2011107583A1 (en) 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
EP2611759A1 (en) 2010-09-03 2013-07-10 Ivax International Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
CA2847736A1 (en) 2011-09-07 2013-03-14 IVAX International GmbH A new polymorphic form of pridopidine hydrochloride
TWI579272B (zh) * 2011-12-08 2017-04-21 梯瓦製藥國際有限責任公司 普多比啶(pridopidine)之氫溴酸鹽
JP6177875B2 (ja) 2012-04-04 2017-08-09 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーTeva Pharmaceuticals International GmbH 併用療法のための医薬組成物
SG11201509729YA (en) 2013-06-21 2015-12-30 Teva Pharmaceuticals Int Gmbh Use of high dose pridopidine for treating huntington's disease
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
EA201691454A1 (ru) 2014-01-22 2017-01-30 Тева Фармасьютикалз Интернэшнл Гмбх Композиции придопидина модифицированного высвобождения
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
CA2970799A1 (en) * 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
MX378579B (es) 2015-02-25 2025-03-11 Prilenia Neurotherapeutics Ltd Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
AR105434A1 (es) * 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
DK3419622T3 (da) 2016-02-24 2024-06-03 Prilenia Neurotherapeutics Ltd Behandling af neurodegenerativ øjensygdom med pridopidin
MX2019002190A (es) 2016-08-24 2019-09-11 Prilenia Therapeutics Dev Ltd Uso de pridopidina para tratar distonías.
EP4516356A3 (en) 2016-08-24 2025-05-14 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline
US20200375966A1 (en) 2016-09-15 2020-12-03 Prilenia Therapeutics Development Ltd Use of pridopidine for the treatment of anxiety and depression
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
PL4005570T3 (pl) 2016-09-16 2024-09-23 Prilenia Neurotherapeutics Ltd. Pridopidyna do zastosowania w leczeniu zespołu retta
PL3570940T3 (pl) 2017-01-20 2024-06-17 Prilenia Neurotherapeutics Ltd. Pridopidyna do zastosowania w leczeniu zespołu łamliwego chromosomu x
EP3357909A1 (en) 2017-02-02 2018-08-08 Sandoz AG Crystalline 4-[3-(methylsulfonyl)phenyl]-1-propyl-piperidine
EP4620471A3 (en) 2017-08-14 2025-11-26 Prilenia Neurotherapeutics Ltd. Treating amyotrophic lateral sclerosis with pridopidine
EA202090542A1 (ru) 2017-08-30 2020-06-08 Приления Ньюротерапьютикс Лтд. Высококонцентрированные лекарственные формы придопидина
EP3678664A1 (en) 2017-09-08 2020-07-15 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
WO2020161707A1 (en) 2019-02-04 2020-08-13 Prilenia Neurotherapeutics Ltd. Low dose pridopidine for parkinson's disease and other diseases associated with parkinsonism
CA3167214A1 (en) 2020-02-13 2021-08-19 Michal Geva Combination therapy for treating amyotrophic lateral using pridopidine and another active agent
WO2023214412A1 (en) 2022-05-03 2023-11-09 Prilenia Neurotherapeutics Ltd. Processes and intermediates for the preparation of pridopidine
WO2026038220A1 (en) 2024-08-15 2026-02-19 Prilenia Neurotherapeutics Ltd. Taste-masked pridopidine formulations, method of use thereof and process for preparation thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB850662A (en) 1956-10-22 1960-10-05 Parke Davis & Co Substituted piperazines and processes for their production
BE662455A (es) * 1964-04-14
FR1459013A (fr) 1964-08-05 1966-04-29 Allen & Hanburys Ltd Procédé de préparation de dérivés de la 4-phényl-pipéridine
GB1060160A (en) 1964-08-05 1967-03-01 Allen & Hanburys Ltd 4-phenylpiperidine derivatives
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US4048314A (en) * 1974-12-17 1977-09-13 Delmar Chemicals Limited Morpholino containing 4-arylpiperidine derivatives
GB1560271A (en) 1977-01-14 1980-02-06 Joullie International Sa Therapeutically useful m-trifluoromethylphenylpiperazine derivatives
US4202898A (en) * 1978-06-05 1980-05-13 Synthelabo Method of treating anxiety and depression
FR2459797A2 (fr) 1978-08-01 1981-01-16 Synthelabo Derives de phenyl-1 piperazine et leur application en therapeutique
US4333942A (en) * 1979-08-03 1982-06-08 Byk Gulden Lomberg Chemische Fabrik Gmbh Anti-depressant and analgesic 4-phenoxypiperidines
US4518712A (en) 1980-06-30 1985-05-21 Taiho Pharmaceutical Company Limited Piperazine derivative and analgesic composition containing the same
GB2083476B (en) 1980-09-12 1984-02-08 Wyeth John & Brother Ltd Heterocyclic compounds
FR2501506A1 (fr) 1981-03-11 1982-09-17 Sanofi Sa Compositions pharmaceutiques a action anorexigene contenant des derives de la tetrahydropyridine
US4415736A (en) * 1981-12-28 1983-11-15 E. I. Du Pont De Nemours & Co. Certain tetrahydropyridine intermediates
US4485109A (en) * 1982-05-07 1984-11-27 E. I. Du Pont De Nemours And Company 4-Aryl-4-piperidinecarbinols
EP0094159B1 (en) 1982-05-10 1990-03-14 Takeda Chemical Industries, Ltd. Dihydropyridine derivatives, their production and use
US4504660A (en) * 1982-07-06 1985-03-12 American Home Products Corporation Process for the production of 2,6-diaminobenzonitrile derivatives
HU198454B (en) 1987-12-14 1989-10-30 Richter Gedeon Vegyeszet Process for production of new derivatives of tetrahydrospiridin and medical compositions containing these compounds
FR2639226B1 (fr) 1988-11-18 1993-11-05 Sanofi Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs
CA2071897A1 (en) 1989-12-28 1991-06-29 Richard A. Glennon Sigma receptor ligands and the use thereof
DK0641320T3 (da) * 1991-04-17 2001-08-20 Upjohn Co Substituerede (S)-3-phenylpiperidinderivater, deres fremstilling og deres anvendelse som dopaminautoreceptorantagonister
PT100639A (pt) 1991-06-27 1993-09-30 Univ Virginia Commonwealth Metodo para o tratamento terapeutico com compostos que sao ligandos ao receptor sigma e compostos ai utilizados, nomeadamente derivados fenilalquil-amina, aminotetralina,piperazina e piperidina
NZ240863A (en) 1991-09-11 1995-04-27 Mcneilab Inc Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof
ES2162792T3 (es) 1991-09-18 2002-01-16 Glaxo Group Ltd Derivados de benzanilida como antagonistas de 5-ht1d.
GB9119932D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
GB9119920D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
US5502050A (en) * 1993-11-29 1996-03-26 Cornell Research Foundation, Inc. Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis
CA2144669A1 (en) 1994-03-29 1995-09-30 Kozo Akasaka Biphenyl derivatives
ES2225979T3 (es) * 1996-07-22 2005-03-16 Daiichi Suntory Pharma Co., Ltd. Derivados de arilpiperidinol y de arilpiperidina y farmacos que los contienen.
US5892041A (en) * 1996-08-12 1999-04-06 Neurogen Corporation Fused indolecarboxamides: dopamine receptor subtype specific ligands
DE19637237A1 (de) 1996-09-13 1998-03-19 Merck Patent Gmbh Piperazin-Derivate
US6232326B1 (en) 1998-07-14 2001-05-15 Jodi A. Nelson Treatment for schizophrenia and other dopamine system dysfunctions
DE60025604T2 (de) 1999-06-22 2006-07-27 Neurosearch A/S Benzimidazol-derivate und diese enthaltende pharmazeutische zusammensetzungen
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
AU2001280599A1 (en) 2000-07-15 2002-01-30 Smith Kline Beecham Corporation Compounds and methods
CA2432985A1 (en) 2001-01-23 2002-08-01 Vincent Mancuso Piperazine- and piperidine-derivatives as melanocortin receptor agonists
US20050004164A1 (en) 2003-04-30 2005-01-06 Caggiano Thomas J. 2-Cyanopropanoic acid amide and ester derivatives and methods of their use
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
EP2204363A1 (en) 2004-06-08 2010-07-07 NSAB, Filial af NeuroSearch Sweden AB, Sverige New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission
SE0401465D0 (sv) 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
US7884104B2 (en) 2004-10-01 2011-02-08 Merck Sharp & Dohme Corp. Aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
CA2584833A1 (en) 2004-10-13 2006-04-20 Neurosearch Sweden Ab Process for the synthesis of 4-(3-sulfonylphenyl)-piperidines
WO2006040155A1 (en) 2004-10-13 2006-04-20 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
SE529246C2 (sv) 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
WO2007065655A1 (en) 2005-12-07 2007-06-14 Neurosearch Sweden Ab Disubstituted phenylpiperidines as modulators of cortical catecholaminergic neurotransmission

Also Published As

Publication number Publication date
CN101056854A (zh) 2007-10-17
AU2005293754A1 (en) 2006-04-20
CA2584831A1 (en) 2006-04-20
PL1802573T3 (pl) 2017-03-31
HUE029790T2 (hu) 2017-04-28
KR20070065911A (ko) 2007-06-25
US20070238879A1 (en) 2007-10-11
JP2008515951A (ja) 2008-05-15
MX2007004215A (es) 2007-12-12
HK1105195A1 (zh) 2008-02-06
US7923459B2 (en) 2011-04-12
CN101056854B (zh) 2013-06-05
AU2005293754B2 (en) 2011-07-21
EP1802573B1 (en) 2016-09-28
JP4891908B2 (ja) 2012-03-07
CA2584831C (en) 2013-09-17
DK1802573T3 (en) 2016-12-19
EP1802573A1 (en) 2007-07-04
WO2006040155A1 (en) 2006-04-20
NZ555094A (en) 2009-07-31
KR101319235B1 (ko) 2013-10-16

Similar Documents

Publication Publication Date Title
ES2659577T3 (es) Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina
JP4795435B2 (ja) エソメプラゾール及びその塩の製造方法
ES2433236T3 (es) Procedimiento para la purificación de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo
JP2018502909A5 (es)
CN112047888B (zh) 一种合成恩杂鲁胺的方法
EA018796B1 (ru) Способ получения 2-(2-пиридинилметилсульфинил)-1н-бензимидазолов
JP2019194203A (ja) フェブキソスタットの調製のための新規方法
SU629881A3 (ru) Способ получени производных тиазоло (3,4 - ) изохинолина или их оптических изомеров или их солей
ES2320172T3 (es) Procedimiento para la produccion de 5-(4-(4-(5-ciano-3-indolil)-butil)-1-piperazinil)-benzofuran-2-carboxamida.
JP4485192B2 (ja) トロペノールの工業的製造方法
CN115260118B (zh) 一种dntf的制备方法
US4076728A (en) Process for manufacturing crystal violet lactone
WO2016143655A1 (ja) 1,2,4-オキサジアゾール誘導体の製造方法
CN104803978A (zh) 一种埃索美拉唑镁的制备方法
ES2289406T3 (es) Procedimiento para preparar pantoprazol y sus sales.
TW201527287A (zh) 二胺基吩噻鎓化合物之純化方法
ES2356501T3 (es) Procedimiento para la preparación de zolmitriptan.
CN110526913A (zh) 一种抗凝药物阿哌沙班相关物质的制备方法
CN106146486A (zh) 一种制备高纯度高收率鲁拉西酮的方法
CN101624377A (zh) 一种合成瑞舒伐他汀钙关键中间体的方法
CN102108049A (zh) 9-芴甲酸的制备方法
CN114763343A (zh) 一种西酞普兰或s-西酞普兰的纯化方法
CN114621188A (zh) 一种泮托拉唑的制备方法
JP5751177B2 (ja) ルテニウム含有化合物及びその製造方法
US10696633B2 (en) Process for the preparation of fexofenadine and of intermediates used therein